跳至主要内容
临床试验/NCT00092183
NCT00092183已完成4 期

A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy

Merck Sharp & Dohme LLC0 个研究点目标入组 866 人开始时间: 2002年10月10日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
866
主要终点
Safety and tolerability

研究概览

简要总结

This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4 cycles of non-cisplatin moderately emetogenic chemotherapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.

排除标准

  • •Patient has a central nervous system malignancy.
  • •Patient will receive radiation to the abdomen or pelvis.

结局指标

主要结局

Safety and tolerability

Emesis and use of rescue medication

次要结局

  • Quality of life

研究者

申办方类型
Industry
责任方
Sponsor

相似试验